Gold and BINOL-Phosphoric Acid Catalyzed Enantioselective Hydroamination/N-Sulfonyliminium Cyclization Cascade
摘要:
A highly enantioselective hydroamination/N-sulfonyliminium cyclization cascade is reported using a combination of gold(I) and chiral phosphoric acid catalysts. An initial 5-exo-dig hydroamination and a subsequent phosphoric acid catalyzed cyclization process provide access to complex sulfonamide scaffolds in excellent yield and high enantiocontrol. The method can be extended to lactam derivatives, with excellent yields and enantiomeric excesses of up to 93% ee.
[EN] N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR<br/>[FR] N-(2-ARYLETHYL)BENZYLAMINES UTILISEES EN TANT QU'ANTAGONISTES DU RECEPTEUR 5-HT6
申请人:LILLY CO ELI
公开号:WO2002078693A2
公开(公告)日:2002-10-10
The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
本发明提供了式(I)的化合物,它们是5-HT6受体的拮抗剂。
N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
申请人:Chen Zhaogen
公开号:US20060009511A9
公开(公告)日:2006-01-12
The present invention provides compounds of formula (I), which are antagonists of the 5-HT
6
receptor.
本发明提供了式(I)的化合物,它们是5-HT6受体的拮抗剂。
N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR
申请人:Chen Zhaogen
公开号:US20070099909A1
公开(公告)日:2007-05-03
The present invention provides compounds of formula (I), which are antagonists of the 5-HT
6
receptor.
本发明提供了公式(I)的化合物,它们是5-HT6受体的拮抗剂。
Pyrazole amide derivative
申请人:AMGEN INC.
公开号:US09365522B2
公开(公告)日:2016-06-14
The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.